期刊
CELL-BASED THERAPY FOR RETINAL DEGENERATIVE DISEASE
卷 53, 期 -, 页码 111-121出版社
KARGER
DOI: 10.1159/000358409
关键词
-
资金
- NEI NIH HHS [R21 EY023812, R21 EY017155, R21 EY019737, R01 EY023754, T32 EY007143, R43 EY023495, P30 EY001765, R01 EY009769, R21 EY022769] Funding Source: Medline
- NIGMS NIH HHS [T32 GM007445] Funding Source: Medline
Retinal ganglion cells (RGCs) represent an essential neuronal cell type for vision. These cells receive inputs from light-sensing photoreceptors via retinal interneurons and then relay these signals to the brain for further processing. RGC diseases that result in cell death, e. g. glaucoma, often lead to permanent damage since mammalian nerves do not regenerate. Stem cell differentiation can generate cells needed for replacement or can be used to generate cells capable of secreting protective factors to promote survival. In addition, stem cell-derived cells can be used in drug screening research. Here, we discuss the current state of stem cell research potential for interference in glaucoma and other optic nerve diseases with a focus on stem cell differentiation to RGCs. (C) 2014 S. Karger AG, Basel
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据